Source: Geron Corporation
Date: June 12, 2008
Summary:
In an official company news release, Geron Corporation, a biotechnology company in the field of stem cell research, reported its embryonic stem cell therapy to treat heart failure evaded attack by the immune system:
"Geron Corporation announced the presentation of research studies indicating that GRNCM1, the company's human embryonic stem cell (hESC)–based therapeutic for the treatment of heart failure, evades direct attack by the human immune system in vitro. The data presented at the International Society for Stem Cell Research (ISSCR) Annual Meeting indicate that, unlike whole organ transplants, cell therapies derived from hESCs may provoke only minimal immune reactions suggesting that rejection may be controlled or prevented by short courses of low–dose immunosuppressive drugs. The work also suggests that patient–specific hESC lines may not be needed to prevent immune rejection."
